Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Once Versus Thrice Daily Colistin in Critically Ill Ptients with Multi-Drug Resistant Infections
  6. Scopus by Title (Ref)

IJ Pharmaceutical Research

Home
Current IssueAll IssuesIn PressAccepted Manuscripts
SearchInstructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Optimal dosing interval of intravenous Colistin monotherapy versus combination therapy: A systematic review and meta-analysis

- Ahmadpour F. , et al.

2. Antibiotics utilization patterns and dosage appropriateness among patients receiving hemodialysis

- Al Himali N. , et al.

3. Antibiotic prescribing trends before and after implementation of an audit and feedback program in internal ward of a tertiary hospital in tehran

- Golali E. , et al.

4. Interim study: Comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/ sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant acinetobacter

- Mosaed R. , et al.

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.